<?xml version="1.0" encoding="UTF-8"?>
<p>Both relapse-free and overall survival rates were non-significantly inferior in the everolimus arm (
 <xref ref-type="fig" rid="f4-1031654">Figure 4C,D</xref>), reflecting the adverse hazard ratios for both relapse and death in remission, with no evidence of differences in salvage between arms after relapse [relapse-free survival: 29% 
 <italic>versus</italic> 40%, HR 1.19 (0.90-1.59), 
 <italic>P</italic>=0.2; overall survival: 45% 
 <italic>versus</italic> 58%, HR 1.30 (0.94-1.81), 
 <italic>P</italic>=0.11]. A sensitivity analysis censoring patients at the time of stem cell transplantation showed results which were consistent with the overall analysis (
 <xref rid="t2-1031654" ref-type="table">Table 2</xref>).
</p>
